News Headline Summary
Eli Lilly (LLY) reaffirms forecast for 2012
- Sees Q4 charge in the range of USD 20-35mln pretax
- Sees about USD 0.02 charge.
- Elsewhere, the company has stopped one of three phase 3 Rheumatoid Arthritis registration, cites did not meet efficacy views.
13 Dec 2012 - 22:01
Subscribe Now to RANsquawk
Click here for a 1 week free trial
RANsquawk provides audio news and commentary for over 15,000
professional traders and brokers worldwide. Services include:
Real-time audio coverage from 0630 to 2130 London time
Teams of analysts covering equities, fixed income, FX and energy markets
Real-time scrolling news service
Daily and weekly pre-market research and calendars
Intra-day market update videos
Daily technical analysis